Insider Selling: Mark Pruzanski Sells 10,000 Shares of Intercept Pharmaceuticals Stock (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) CEO Mark Pruzanski sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total value of $2,267,200.00. Following the completion of the transaction, the chief executive officer now directly owns 475,042 shares in the company, valued at approximately $107,701,522. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on ICPT shares. Analysts at Nomura upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 29th. They now have a $323.00 price target on the stock. Separately, analysts at Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 14th. They set a “buy” rating and a $395.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $454.20.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 1.57% during mid-day trading on Wednesday, hitting $223.48. The stock had a trading volume of 233,909 shares. Intercept Pharmaceuticals has a one year low of $42.41 and a one year high of $497.00. The stock has a 50-day moving average of $236.5 and a 200-day moving average of $293.9. The company’s market cap is $4.713 billion.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.